Ascletis Pharma Inc (2VJ) - Total Assets
Based on the latest financial reports, Ascletis Pharma Inc (2VJ) holds total assets worth €2.07 Billion EUR (≈ $2.42 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 2VJ cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Ascletis Pharma Inc - Total Assets Trend (2016–2025)
This chart illustrates how Ascletis Pharma Inc's total assets have evolved over time, based on quarterly financial data. See Ascletis Pharma Inc (2VJ) net assets for net asset value and shareholders' equity analysis.
Ascletis Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ascletis Pharma Inc's total assets of €2.07 Billion consist of 92.9% current assets and 7.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 69.9% |
| Accounts Receivable | €223.00K | 0.0% |
| Inventory | €1.87 Million | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €10.29 Million | 0.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Ascletis Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 2VJ stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ascletis Pharma Inc's current assets represent 92.9% of total assets in 2025, an increase from 86.9% in 2016.
- Cash Position: Cash and equivalents constituted 69.9% of total assets in 2025, down from 78.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 0.5% of total assets.
Ascletis Pharma Inc Competitors by Total Assets
Key competitors of Ascletis Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Ascletis Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.05 | 12.88 | 38.36 |
| Quick Ratio | 15.04 | 12.85 | 37.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.79 Billion | €1.82 Billion | €2.76 Billion |
Ascletis Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Ascletis Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.66 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | €2.07 Billion |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ascletis Pharma Inc's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Ascletis Pharma Inc's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Ascletis Pharma Inc (2016–2025)
The table below shows the annual total assets of Ascletis Pharma Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.07 Billion ≈ $2.42 Billion |
-2.73% |
| 2024-12-31 | €2.12 Billion ≈ $2.48 Billion |
-14.71% |
| 2023-12-31 | €2.49 Billion ≈ $2.91 Billion |
-6.25% |
| 2022-12-31 | €2.66 Billion ≈ $3.11 Billion |
-6.11% |
| 2021-12-31 | €2.83 Billion ≈ $3.31 Billion |
-7.73% |
| 2020-12-31 | €3.07 Billion ≈ $3.59 Billion |
-10.49% |
| 2019-12-31 | €3.43 Billion ≈ $4.01 Billion |
-2.87% |
| 2018-12-31 | €3.53 Billion ≈ $4.12 Billion |
+255.87% |
| 2017-12-31 | €991.25 Million ≈ $1.16 Billion |
+84.84% |
| 2016-12-31 | €536.26 Million ≈ $626.95 Million |
-- |
About Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more